Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China

Launched by DAIICHI SANKYO · Aug 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how patients in China are treated for neuropathic pain, specifically focusing on two types: diabetic peripheral neuropathic pain (DPNP) and chemotherapy-induced peripheral neuropathy (CIPN). The goal is to understand what medications are commonly prescribed and how effective they are for managing pain.

To participate, you should be at least 18 years old and have been diagnosed with either DPNP or CIPN in the last few years. You need to have received at least one specific medication for your pain and have had a medical visit within the past year. However, if you have certain mental health conditions, like epilepsy or schizophrenia, you won't be eligible. Participants can expect to share their treatment experiences, which will help researchers learn more about effective pain management for these conditions. This study is currently recruiting participants, and your involvement could contribute to better care for others suffering from similar pain.

Gender

ALL

Eligibility criteria

• • Participants who meet all the following criteria will be included in the DPNP cohort.
• • 1. Participants were diagnosed with diabetic neuropathy and presented with the pain symptom between 1st January 2018 and 31st December 2021;
• • 2. Participants received at least one targeted medication between 1st January 2018 and 31st December 2021;
• • 3. Participants were ≥18 years on the index date;
• • 4. Participants had at least one medical visit record within 12 months after the index date
• • Participants who meet any one of the following criteria will be excluded from the DPNP cohort.
• • (1) Participants were diagnosed with epilepsy, schizophrenia, or bipolar disorder before or on the index date
• • Participants who meet all the following criteria will be included in the CIPN cohort.
• • 1. Participants had neuropathy that was induced by the chemotherapy between 1st January 2018 and 31st December 2021, regardless of the presence of pain symptoms;
• • 2. Participants received at least one targeted medication between 1st January 2018 and 31st December 2021;
• • 3. Participants were ≥18 years on the index date;
• • 4. Participants had at least one medical visit record within12 months after the index date
• • Participants who meet any one of the following criteria will be excluded from the CIPN cohort.
• • 1. Participants were diagnosed with epilepsy, schizophrenia, or bipolar disorder before or on the index date;
• • 2. Participants had neuralgia or neuropathy caused by tumor metastasis or non-chemotherapy-induced factors (e.g., radiotherapy, myasthenia gravis syndrome, paraneoplastic syndrome, direct tumor invasion, local tissue compression, postoperative traumatic pain, immune therapy-related pain, comorbidity-induced pain, etc.)